Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

AtriCure Reports Deeper Losses In Q4 Despite 27% Jump In Sales, Issues FY22 Guidance

AtriCure Inc (NASDAQ:ATRC) reported Q4 FY21 sales of $73.2 million, an increase of 26.8% Y/Y (+27.4% on a constant currency basis), beating the consensus of $72.65 million.

  • U.S. revenue was $61.2 million, increasing 29.1% reflected strong growth across all product lines, driven by sales of cryoSPHERE, EPi-Sense, and AtriClip Flex⋅V products. 
  • International revenue increased 16.3% (+19.3% on a constant currency basis) to $12.0 million, reflecting growth in most major markets and across product lines. 
  • The gross margin was 75.1% and 73.5% for the fourth quarters of 2021 and 2020, respectively, reflecting a favorable geographic and product mix.
  • Loss from operations was $(12.5) million, compared to $(17.5) million a year ago.
  • The Company reported an EPS loss of $(0.30) down from $(0.18) a year ago and missing the consensus of $(0.29).
  • Adjusted EBITDA was negative for Q4 2021 at $(2.1) million, compared to a positive $1.7 million in Q4 FY20.
  • Guidance: AtriCure projects FY22 sales of approximately $315 million - $330 million (consensus of $319.44 million), reflecting about 15% to 20% growth. 
  • Continued uncertainty relating to the dynamic environment with the COVID-19 pandemic could materially impact the projection. 
  • FY22 adjusted EBITDA is expected to be a loss of approximately $(2) million - $(4) million, with an adjusted EPS loss of $(1.07) to $(1.12).
  • Price Action: ATRC shares closed at $65.50 on Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.